Johnson & Johnson's DePuy Synthes arm plans to spend more than $36 million to build up a research-and-development operation in Ireland.
With the American Society of Hematology meeting in New Orleans, a slew of blood cancer studies are in the spotlight. Three of the releases caught our eye, because they're significant new data on drugs already on the market.
Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.
Charles River Laboratories has convinced the CEO of Memorial Sloan-Kettering Cancer Center to join its board of directors, leading a new committee to ensure the CRO stays on the cutting edge of science.
Massachusetts CRO Agilux Laboratories has expanded its in vivo pharmacokinetics footprint, boosting its ability to run preclinical drug-response tests for a growing list of clients.
Vaccines have basically worked the same way for decades. A pathogen antigen is isolated, used as the basis of a vaccine and administered to the patient. The Pentagon thinks there might be a better way of doing things, and it has tasked Pfizer with investigating its hunch.
Last winter, Google Flu Trends was shown to be a work in progress when it wildly overestimated incidence of influenza, but its algorithm-based model has considerable potential.
Geron got an early gift from its friends at the Mayo Clinic, as a release of upbeat imetelstat results sent its shares skyward Friday morning, rising as much as 30% in premarket trading on news its myelofibrosis drug triggered complete remission in some patients.
Novartis' in-development multiple myeloma candidate LBH589 hit its primary endpoint of staving off cancer progression in a late-stage study, the company said, stoking hopes the Swiss drugmaker can take first place among a new class of treatments.
Well-traveled biotech luminary Michael Foley has agreed to head up a new translational research effort that unites minds at Weill Cornell Medical College, the Rockefeller University and Memorial Sloan-Kettering Cancer Center with the mission of turning exciting lab work into promising drug candidates.